Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
  Pharmaceutical Technology Europe E-Alert
 
26 October 2012

IN THIS ISSUE
Roche investigated
Ben Venue production
Cell-based therapies
Dr Reddy's & OctoPlus
Watson & Actavis
Twitter

 
Roche Under EMA Investigation
The European Medicines Agency has launched an infringement procedure against Roche to investigate the alleged pharmacovigilance deficiencies that were uncovered during an inspection earlier this year. More...
 
Ben Venue Resumes Limited Production
Ben Venue Laboratories has resumed production on a limited number of manufacturing lines in the company’s Bedford, Ohio, facilities in the US. More...
 
Europe Establishes First Facility for Cell-Based Therapeutics
A consortium in France has announced the establishment of Europe’s first ever industrial manufacturing facility dedicated to the large-scale production of novel, advanced cell-based therapy medicinal products. More...
 
Dr. Reddy's Announces Plans to Acquire OctoPlus for EUR 27 Million
Dr. Reddy's is planning to acquire the specialty injectable company OctoPlus for approximately EUR 27.4 million ($35.7 million) in cash to strengthen its technological capabilities in drug delivery. More...
 
Watson Receives Clearance for Actavis Acquisition
Watson Pharmaceuticals has received clearance from the Federal Trade Commission for its acquisition of the generic drug manufacturer, Actavis, for $5.6 billion. More...
 
Get the Latest Updates on Twitter
We regularly tweet the latest news and rumours hitting the web about the pharmaceutical industry. Follow us to keep up to date. More...
Key Topics:

Latest blog posts
Eli Lilly Chariman Stresses the Importance of Biopharmaceutical Innovation on the Economy
FDA Reg. Science Initiative Moving Along with Academic Help
Recognising Pharma Innovation
More blog posts

Latest articles
Supplier Qualification
Integration of Less-Formal Risk Assessment Tools into Change Control
Seeking Solutions in Solid-State Chemistry
More articles

Upcoming events
Lab Innovations 2012 (7–8 November | UK)
BioEurope 2012 (12–14 November | Germany)
The GMP Compliance Manager (15–16 November | Hungary)
More events

Products/Service Profiles
Agilent

Realize Effective Pharmaceuticals
Reliable solutions enable pharmaceutical scientists to innovate in disease research, accelerate drug discovery and have greater confidence throughout development and manufacturing. Agilent solutions in genomics research, automation, separation and detection technologies along with workflow driven software solutions helps deliver the answers to bring effective therapeutics to market.
Learn more at www.agilent.com/lifesciences/realizepharma

 
Agilent

Agilent ICP-MS/ICP-OES
Reliable solutions for regulated pharmaceutical laboratories

Complying with new elemental impurity limits as defined by draft USP methods <232>/<233> could pose a significant challenge. You need to choose qualified hardware and software, ensure verification, and maintain electronic records. But there is a simple answer – Request a free copy of our primer on Elemental Impurity Analysis to learn more.

 
Shimadzu

The world's fastest LCMS/MS tandem mass spectrometer
Shimadzu has introduced the LCMS-8040 which combines newly improved ion optics and collision cell technology with proprietary ultrafast technologies. This significantly expands the application range and ensures high-sensitivity, high-throughput analysis at lower levels of detection. Read more


Special Supplement

Solubilization Solutions
In a special PharmTech issue, current and emerging bioavailability challenges are examined. Articles address solutions and approaches for solubilization as related to solid dispersions by hot-melt extrusion, lipophilic excipients, lipid-based formulations, spray drying, and more.
Read more

Survey
Do you think the growing number of anticounterfeiting technologies, coupled with increased focus from regulators, have had a positive impact on reducing the number of counterfeit pharmaceuticals in the legal supply chain?
 
Yes 53%
 
 
No 14%
     
 
Technologies have; regulations are still inadequate 26%
     
 
Regulations have; technologies are still inadequate 7%

This week we would like to know...

Concerns have recently been raised about the safety of confidential data at FDA. Do you think regulators are doing enough to protect confidential data?

Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.